Drug Database
ME

meningococcal polysaccharide AC vaccine (Mengllingkang)

✓ Approved

China National Biotec Group · 疫苗 · 疫苗

什么是 meningococcal polysaccharide AC vaccine?

meningococcal polysaccharide AC vaccine 是一种疫苗,由China National Biotec Group研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Mengllingkang
公司China National Biotec Group
药物类别疫苗
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

治疗适应症

meningococcal polysaccharide AC vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedJournal of the science of food and agriculture2026-09-11

Antioxidant and anti-aging effects of polysaccharides extracted from Camellia oleifera branches.

Lu Shengjia S, Xin Jianghui J, Cheng Ligui L, Ou Yanghui Y et al.

Camellia oleifera Abel is extensively cultivated for edible oil, generating abundant leaves, shells, and branches as by-products. However, the bioactivity of polysaccharides from these different tissues remains poorly characterized. To valorize these agricultural wastes, six crude polysaccharides were extracted from the leaves, shells, and branches of C. oleifera using hot water extraction (HWE) and ultrasound-assisted hot water extraction (USHWE). Their physicochemical properties were compared, and in vitro anti-inflammatory effects were evaluated to identify the most promising fraction. The active polysaccharide was purified, and its in vivo anti-aging potential was investigated in Caenorhabditis elegans. Physicochemical characterization revealed distinct structural and compositional differences among the six polysaccharides. Notably, the polysaccharide obtained from branches by HWE (HWE-Branch), which possessed a high total sugar content (35.35%), showed the most potent suppression of lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and interleukin-1β (IL-1β) expression in RAW264.7 macrophages, exceeding the effect of dexamethasone. This fraction was purified to yield a homogeneous polysaccharide designated C. oleifera branch polysaccharide (CBP). In C. elegans, CBP extended lifespan in a concentration-dependent manner; at 4 mg mL-1, the median lifespan increased by 32.6% compared with the control. Under cyclic heat stress, 4 mg mL-1 CBP maintained 38.38% survival after four cycles, whereas all control nematodes died. Furthermore, CBP significantly reduced intracellular reactive oxygen species (ROS) and lipofuscin levels. At 4 mg mL-1, ROS fluorescence intensity decreased from 48.84% to 21.79% and lipofuscin from 25.03% to 10.23%. Purified C. oleifera branch polysaccharide CBP showed strong anti-aging effects in C. elegans by scavenging ROS, attenuating lipofuscin accumulation, and enhancing stress resistance. These findings indicate that CBP is a promising natural ingredient for anti-aging interventions and support the valorization of C. oleifera processing by-products. © 2026 Society of Chemical Industry.

PMID 42723275
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-09-11

Solvent-Chirality-Gated Recognition of Carbon Nanotubes by Polysaccharides.

Yoshida Kazuhiro K, Hatakeyama Yoshikiyo Y, Nonoguchi Yoshiyuki Y

Chiral molecular recognition is typically achieved through static complementarity between chiral hosts and molecular guests. Dynamic control of such recognition through external stimuli remains an important challenge, particularly for interactions involving extended solid surfaces. Here we show that solvent chirality can act as an external control parameter that modulates the conformation of polysaccharide dispersants and thereby creates a tunable chiral recognition field for one-dimensional nanomaterials. By continuously varying the enantiomeric excess of chiral solvents, the conformation of cellulose acetate can be modulated, resulting in switchable selectivity in the extraction of semiconducting single-walled carbon nanotubes (SWCNTs). Spectroscopic and structural analyses reveal that solvent chirality alters the balance between inter- and intramolecular interactions within the polysaccharide, leading to distinct conformational states that influence nanotube recognition. These findings demonstrate that chiral solvation can dynamically modulate macromolecular recognition fields and provide a strategy for controlling interactions between soft matter and extended solid nanostructures.

PMID 42723392
阅读全文 →
PubMedFrontiers in microbiology2026-09-11

Xy-31 and Lat-1 regulate the induction of polysaccharide disintegrating genes by arabinose in Neurospora crassa OR74A.

Singh Shriya S, Adlakha Nidhi N

Arabinose has been identified as a potent inducer of the cellulase regulon in filamentous fungi. However, the precise molecular mechanisms that drive this induction remain largely unknown. This study aimed to elucidate the mechanisms underlying the arabinose-induced activation of cellulase and hemicellulase enzyme clusters in the model filamentous fungus Neurospora crassa OR74A. Arabinose stimulates the secretion of cellulases and hemicellulases in N. crassa. While genome-wide scrutiny predicted several sugar transporters in N. crassa, expression studies under avicel and arabinan conditions indicated a notable upregulation of pentose transporters encoded by the lat-1 and xy-31 genes. The lat-1 and xy-31 deleted strains showed reduced arabinose uptake and diminished growth on arabinose media, highlighting their role in arabinose transport. Additionally, these transporter-deficient strains exhibited a significant decrease in endoglucanase and arabinase activity, which correlated with lower expression of cellulase-encoding transcripts, indicating the crucial roles of Lat-1 and Xy-31 in promoting the secretion of enzymes that degrade biomass. Consistent with these findings, overexpression of lat-1 and xy-31 in N. crassa resulted in a significant increase in cellulase secretion. We demonstrated that N. crassa has multiple pentose transporters. Furthermore, we validated that the Lat-1 and Xy-31 transporters play crucial roles in arabinose-mediated induction of polysaccharide-disintegrating enzymes in N. crassa. Both transporters are required for efficient arabinose uptake and for the subsequent arabinose-dependent induction of polysaccharide-disintegrating enzymes. Collectively, these findings significantly advance the molecular understanding of fungal hemicellulose utilization and identify key transporters that represent promising targets for enhancing fungal biomass bioconversion.

PMID 42724163
阅读全文 →
PubMedThe New phytologist2026-09-11

Santosh B. Satbhai.

Santosh B. Satbhai, Indian Institute of Science Education and Research (IISER) Mohali (India).

PMID 42722984
阅读全文 →
PubMedTherapeutic advances in vaccines and immunotherapy2026-09-11

Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies.

Mhanna Daniel D, Salman Bilal B, El Hakim Rawad R, Aridi Lea L et al.

Melanoma has emerged as a major focus of cancer immunotherapy research because of its highly immunogenic nature and responsiveness to immune-based treatments. Therapeutic melanoma vaccines are designed to stimulate tumor-specific immune responses through the delivery of Tumor-Associated Antigens (TAAs), Tumor-Specific Antigens (TSAs), and personalized neoantigens. This narrative review provides an overview of current melanoma vaccine strategies, including peptide-based vaccines, dendritic cell vaccines, nucleic acid-based platforms such as mRNA, DNA, and viral vector vaccines. Recent advances in vaccine engineering and tumor genomics have accelerated the development of personalized neoantigen vaccines capable of targeting mutations unique to individual tumors. In parallel, Artificial Intelligence (AI) and Machine Learning (ML) are increasingly being incorporated into neoantigen identification pipelines to improve epitope prediction and optimize vaccine design. Combination strategies involving Immune Checkpoint Inhibitors (ICIs), particularly anti-PD-1 and anti-CTLA-4 therapies, have further enhanced interest in melanoma vaccines by helping overcome tumor-induced immune suppression and augment T-cell activation. In addition to reviewing vaccine mechanisms and emerging technologies, this manuscript examines the evolving clinical trial landscape through analysis of melanoma vaccine studies registered on ClinicalTrials.gov. Although many studies have reported encouraging safety and immunogenicity findings, challenges related to tumor heterogeneity, immune evasion, biomarker selection, and manufacturing complexity continue to limit widespread clinical implementation. Ongoing advances in computational immunology, biomaterial engineering, and precision oncology are expected to further refine melanoma vaccine development and improve therapeutic efficacy. Collectively, these innovations may help establish melanoma vaccines as an increasingly important component of future personalized cancer immunotherapy strategies.

PMID 42724148
阅读全文 →
PubMedFrontiers in medicine2026-09-11

Treatment and clinical outcomes among stage II-IVA nasopharyngeal carcinoma patients with undetectable pretreatment Epstein-Barr viral DNA.

Sun Ci-Ming CM, Xu Zhen Z, Li Cheng-Hao CH, Chen Jun-Xiang JX et al.

This study analyzed the efficacy of multiple combined chemotherapy modalities on the long-term survival outcomes in stage II-IVA nasopharyngeal carcinoma (NPC) patients with undetectable pretreatment Epstein-Barr viral DNA (pre-DNA). We retrospectively analyzed 2,440 patients with stage II-IVA NPC with undetectable pre-DNA. Patients received any of the following treatment modalities: intensity-modulated radiotherapy (IMRT) alone; concurrent chemoradiotherapy (CCRT); induction chemotherapy (IC) + CCRT; IC + IMRT; or CCRT + adjuvant chemotherapy (AC) at Sun Yat-sen University Cancer Center between 2009 and 2015. Propensity score matching (PSM) was performed to balance variables. Matched patients in different treatment subgroups were analyzed by comparing survival outcomes. In the PSM cohorts, no significant differences were observed in disease-free survival (DFS), overall survival (OS), distant metastasis-free survival (DMFS), or locoregional relapse-free survival (LRRFS) between patients treated with IMRT combined with multiple chemotherapy modalities and those with IMRT alone (all P > 0.05). The estimated 5-year DFS, OS, DMFS, and LRRFS rates were 85.6% vs. 87.3% (P = 0.33), 93.5% vs. 92.2% (P = 0.64), 94.4% vs. 93.7% (P = 0.96), and 92.0% vs. 94.0% (P = 0.16), respectively. Similarly, no significant differences in 5-year DFS, OS, DMFS, or LRRFS were observed across subgroups receiving IMRT with or without concurrent chemotherapy (CC), IC followed by IMRT with or without CC, or CCRT with or without IC. However, among patients receiving CCRT with or without AC, the 5-year DFS (96.0% vs. 78.3%, P = 0.004), OS (98.0% vs. 88.1%, P = 0.027), and LRRFS (97.9% vs. 87.9%, P = 0.045) rates were significantly higher in patients without AC, whereas no significant difference was observed in DMFS (96.0% vs. 86.1%, P = 0.078). No significant differences in the survival outcomes of T3-4 stage and N2-3 disease were identified. In patients with stage II-IVA NPC with undetectable pre-treatment EBV DNA, the addition of chemotherapy to IMRT was not associated with a statistically significant improvement in survival, regardless of whether they received induction, concurrent, or adjuvant chemotherapy. Further prospective validation is required.

PMID 42723970
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcal polysaccharide AC vaccine